Unknown

Dataset Information

0

PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.


ABSTRACT: Adoptive transfer (AT) of T cells forced to express tumor-reactive T-cell receptor (TCR) genes is an attractive strategy to direct autologous T-cell immunity against tumor-associated antigens. However, clinical effectiveness has been hampered by limited in vivo persistence. We investigated whether the use of major histocompatibility complex-mismatched T cells would prolong the in vivo persistence of tumor-reactive TCR gene expressing T cells by continuous antigen-driven proliferation via the endogenous potentially alloreactive receptor. Donor-derived CD8(+) T cells engineered to express a TCR against a leukemia-associated antigen mediated strong graft-versus-leukemia (GVL) effects with reduced graft-versus-host disease (GVHD) severity when given early after transplantation. AT later after transplantation resulted in a complete loss of GVL. Loss of function was associated with reduced expansion of TCR-transduced T cells as assessed by CDR3 spectratyping analysis and PD-1 up-regulation on T cells in leukemia-bearing recipients. PD-L1 blockade in allogeneic transplant recipients largely restored the GVL efficacy without triggering GVHD, whereas no significant antileukemia effects of PD-L1 blockade were observed in syngeneic controls. These data suggest a clinical approach in which the AT of gene-modified allogeneic T cells early after transplantation can provide a potent GVL effect without GVHD, whereas later AT is effective only with concurrent PD-L1 blockade.

SUBMITTER: Koestner W 

PROVIDER: S-EPMC3035065 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.

Koestner Wolfgang W   Hapke Martin M   Herbst Jessica J   Klein Christoph C   Welte Karl K   Fruehauf Joerg J   Flatley Andrew A   Vignali Dario A DA   Hardtke-Wolenski Matthias M   Jaeckel Elmar E   Blazar Bruce R BR   Sauer Martin G MG  

Blood 20101109 3


Adoptive transfer (AT) of T cells forced to express tumor-reactive T-cell receptor (TCR) genes is an attractive strategy to direct autologous T-cell immunity against tumor-associated antigens. However, clinical effectiveness has been hampered by limited in vivo persistence. We investigated whether the use of major histocompatibility complex-mismatched T cells would prolong the in vivo persistence of tumor-reactive TCR gene expressing T cells by continuous antigen-driven proliferation via the end  ...[more]

Similar Datasets

| S-EPMC5954061 | biostudies-literature
| S-EPMC3625710 | biostudies-literature
| S-EPMC5363727 | biostudies-literature
| S-EPMC3130781 | biostudies-literature
| S-EPMC8063091 | biostudies-literature
| S-EPMC4351071 | biostudies-literature
| S-EPMC3568501 | biostudies-literature
| S-EPMC9980553 | biostudies-literature
| S-EPMC5384367 | biostudies-literature
| S-EPMC9216497 | biostudies-literature